What changed

B100335/2026

P10_TA(2026)0263

European Parliament resolution on the draft Commission implementing decision renewing the authorisation for the placing on the market of products containing, consisting of or produced from genetically modified maize NK603 × T25 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council (D115002/04 – 2026/2745 (RSP))

Genetically modified maize NK603 × T25

– having regard to the draft Commission implementing decision renewing the authorisation for the placing on the market of products containing, consisting of or produced from genetically modified maize NK603 × T25 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council (D115002/04),

PE789.023

European Parliament resolution of 8 July 2026 on the Commission Implementing Decision (EU) 2026/1417 of 29 June 2026 renewing the authorisation for the placing on the market of products containing, consisting of or produced from genetically modified maize NK603 × T25 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council (2026/2745(RSP))

– having regard to the Commission Implementing Decision (EU) 2026/1417 of 29 June 2026 renewing the authorisation for the placing on the market of products containing, consisting of or produced from genetically modified maize NK603 × T25 pursuant to Regulation (EC) No 1829/2003 of the European Parliament and of the Council,

– having regard to Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified food and feed, and in particular Article 11(3) and Article 23(3) thereof,

– having regard to the motion for a resolution of the Committee on the Environment, Climate and Food Safety,

A. whereas Commission Implementing Decision (EU) 2015/2279 authorised the placing on the market of food and feed containing, consisting of, or produced from genetically modified maize NK603 × T25 (‘GM(the ‘GM maize’); whereas the scope of that authorisation also covered the placing on the market of products other than food and feed containing or consisting of the GM maize, for the same uses as any other maize, with the exception of cultivation;

B. whereas on 19 April 2024, Bayer Agriculture BV, based in Belgium, on behalf of Bayer CropScience LP, based in the United States, submitted an application to the Commission for the renewal of that authorisation;

C. whereas on 27 November 2025, EFSA issued a favourable scientific opinion on the GM maize, in accordance with Articles 6 and 18 of Regulation (EC) No 1829/2003; whereas it concluded that the renewal application did not contain evidence of any new hazards, modified exposure or scientific uncertainties that would change the conclusions of the original risk assessment on the GM maize, adopted by the EFSA in 2015; whereas those opinions did not address several broader environmental, socio-economic, and cumulative impacts which EFSA considers to fall outside its remit;

D. whereas the GM maize is a stacked herbicide-tolerant genetically modified maize developed by combining the NK603 event (glyphosate tolerance) and the T25 event (glufosinate ammonium tolerance);

E. whereas the risk assessments carried out by EFSA did not include long-term toxicological studies or detailed analysis of cumulative and combinatorial effects, including potential interactions with residues of pesticides commonly used in maize cultivation;

F. whereas the vast majority of GM crops, including the GM maize, have been genetically modified so that they are tolerant to one or more ‘complementary’ herbicides which can be used throughout the cultivation of the GM crop, without the crop dying, as would be the case for a non-herbicide tolerant crop; whereas a number of studies show that herbicide-tolerant GM crops result in a higher use of complementary herbicides, in large part because of the emergence of herbicide-tolerant weeds;

G. whereas herbicide-tolerant GM crops lock farmers into a weed management system that is largely or wholly dependent on herbicides, and does so by charging a premium for GM seeds while creating a dependency on the use of complementary herbicides as an integral part of the production system; whereas heightened reliance on the complementary herbicides on farms planting the GM maize will accelerate the emergence and spread of weeds resistant to those herbicides, thereby triggering the need for even more herbicide use, a vicious circle known as ‘the herbicide treadmill’; whereas, as a consequence, the adverse impacts stemming from excessive reliance on herbicides will worsen soil health, water quality, and above and below ground biodiversity, as well as leading to increased human and animal exposure, potentially also via increased herbicide residues on food and feed;

H. whereas glufosinate is classified as toxic to reproduction 1B and therefore meets the ‘cut-off criteria’ set out in Regulation (EC) No 1107/2009 of the European Parliament and of the Council; whereas the approval of glufosinate for use in the Union expired on 31 July 2018;

M. whereas Regulation (EC) No 1829/2003 requires that GM food and feed must not have adverse effects on human health, animal health or the environment;

N. whereas Union renewal of the authorisation of the GM maize would not be consistent with international commitments on pesticide reduction, given the increased human, animal and environmental exposure to glyphosate and glufosinate in countries which grow this herbicide-tolerant GM crop, along with the potentially serious associated health outcomes;

O. whereas the cultivation of the GM maize is not allowed in the Union;

P. whereas theCommission draftImplementing CommissionDecision implementing(EU) decision2026/1417 would continue to allow imports into the Union that do not comply with the standards observed by Union farmers, thereby placing them at a competitive disadvantage;

Q. whereas the conclusions of the Strategic Dialogue on the Future of EU Agriculture call on the Commission to reassess its approach on market access for agri-food imports and exports, given the challenge of diverging standards of the Union and its trading partners; whereas fairer trade relations, at a global level, consistent with goals for a healthy environment were one of the main demands of farmers during the demonstrations of 2023, 2024 and 2025;

T. whereas the One Health approach requires taking into account the interdependence between human, animal, plant and environmental health when assessing the long-term sustainability and safety of GMOs;

1. Considers that theCommission draftImplementing CommissionDecision implementing(EU) decision2026/1417 exceeds the implementing powers provided for in Regulation (EC) No 1829/2003;

2. Considers that theCommission draftImplementing CommissionDecision implementing(EU) decision2026/1417 is not consistent with Union law, in that it is incompatible with the aim of Regulation (EC) No 1829/2003, which is, in accordance with the general principles laid down in Regulation (EC) No 178/2002 of the European Parliament and of the Council, to provide the basis for ensuring a high level of protection of human life and health, animal health and welfare, and environmental and consumer interests, in relation to GM food and feed, while ensuring the effective functioning of the internal market;

3. Calls on the Commission to withdrawrepeal itsCommission draftImplementing implementingDecision decision;(EU) 2026/1417;

4. Calls on the Commission not to renew the authorisation of the GM maize due to the lack of sufficient evidence on long-term impacts on biodiversity, food safety, farmers’ livelihoods and animal health, in line with the One Health approach;

5. Calls on the Commission to submit, without delay, a legislative proposal to reform the decision-making procedure on GMOs in order to respond to the consistent objections of Parliament and the lack of qualified majority support among Member States;